Guangdong Taienkang Pharmaceutical Co., Ltd.

XSEC:301263 Stock Report

Market Cap: CN¥6.3b

Guangdong Taienkang Pharmaceutical Management

Management criteria checks 4/4

Guangdong Taienkang Pharmaceutical's CEO is Hanjie Zheng, appointed in Nov 2011, has a tenure of 13.08 years. directly owns 20.87% of the company’s shares, worth CN¥1.32B. The average tenure of the management team and the board of directors is 3.7 years and 5.9 years respectively.

Key information

Hanjie Zheng

Chief executive officer

CN¥487.2k

Total compensation

CEO salary percentagen/a
CEO tenure13.1yrs
CEO ownership20.9%
Management average tenure3.7yrs
Board average tenure5.9yrs

Recent management updates

Recent updates


CEO

Hanjie Zheng (61 yo)

13.1yrs

Tenure

CN¥487,200

Compensation

Mr. Hanjie Zheng is GM & Chairman of Guangdong Taienkang Pharmaceutical Co., Ltd. from November 17, 2011.


Leadership Team

NamePositionTenureCompensationOwnership
Hanjie Zheng
GM & Chairman13.1yrsCN¥487.20k20.87%
CN¥ 1.3b
Guixi Zhou
Accounting Supervisor & Financial Director2yrsCN¥303.10k0.033%
CN¥ 2.1m
Chun Chen
Director & Deputy GM13.1yrsCN¥308.40k0.12%
CN¥ 7.5m
Ting Li
Director4.9yrsCN¥319.50k0.13%
CN¥ 8.4m
Tao Sun
Deputy General Manager2.5yrsCN¥360.00k0.17%
CN¥ 10.8m
Zhen Zhang
Deputy General Manager2.5yrsCN¥714.90k1.42%
CN¥ 90.5m

3.7yrs

Average Tenure

48yo

Average Age

Experienced Management: 301263's management team is considered experienced (3.7 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Hanjie Zheng
GM & Chairman13.1yrsCN¥487.20k20.87%
CN¥ 1.3b
Chun Chen
Director & Deputy GM13.1yrsCN¥308.40k0.12%
CN¥ 7.5m
Ting Li
Director4.9yrsCN¥319.50k0.13%
CN¥ 8.4m
Weiwen Sun
Vice Chairman12.8yrsno data15.64%
CN¥ 992.6m
Chaohui Peng
Independent Directorless than a yearno datano data
Jian-Xin Wang
Supervisor6.8yrsno datano data
Yiyong Shen
Independent Directorless than a yearno datano data
Xiaowei Chen
Independent Directorless than a yearno datano data

5.9yrs

Average Tenure

57.5yo

Average Age

Experienced Board: 301263's board of directors are considered experienced (5.9 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/31 09:08
End of Day Share Price 2024/12/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Guangdong Taienkang Pharmaceutical Co., Ltd. is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Song YangTianfeng Securities Brokerage Co., Ltd
Tielin ChenTopsperity Securities
Xinming ZhouTopsperity Securities